Adrian Hepner, MD, PhD
Adrian has over 25 years of experience in US and international clinical research and drug development. He has been our Chief Medical Officer since January 2015. His experience includes the development and implementation of the clinical and regulatory strategies for a multiple number of products from early-stage development through successful New Drug Application (NDA) and EU regulatory filings.
Prior to Eagle, Adrian’s roles included Vice President of Clinical Research at Avanir Pharmaceuticals, Vice President of Clinical Research and Medical Affairs at BioDelivery Sciences International (BDSI), and Senior Medical Director at UCB BioSciences, Inc. Additionally, he spent 17 years in neuropsychiatry, private practice.
Adrian has published more than 20 papers and has been issued several patents for his work.
Adrian received his MD and PhD from the University of Buenos Aires. He spent a number of years as a post-doctoral fellow in the Neuro-Psychopharmacology at the University of Ottawa. Additionally, Adrian completed visiting research physician experiences in the Department of Psychiatry at Harvard Medical School and the Department of Neurology at the National Institute of mental Health.